Zacks Research Upgrades TransMedics Group (NASDAQ:TMDX) to Hold

TransMedics Group (NASDAQ:TMDX) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

TMDX has been the topic of a number of other research reports. UBS Group decreased their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Canaccord Genuity Group dropped their price target on TransMedics Group from $95.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, October 13th. Barclays began coverage on TransMedics Group in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a report on Friday, September 11th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $115.60.

TransMedics Group Trading Up 1.0%

Shares of TransMedics Group stock opened at $67.34 on Monday. The firm has a market capitalization of $2.33 billion, a PE ratio of 17.31, a price-to-earnings-growth ratio of 0.92 and a beta of 2.14. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The firm’s 50 day moving average is $80.57 and its 200 day moving average is $94.17. TransMedics Group has a 1 year low of $60.10 and a 1 year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The company had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. During the same quarter in the prior year, the company earned $0.92 earnings per share. TransMedics Group’s revenue for the quarter was up 20.7% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director David Weill bought 1,336 shares of TransMedics Group stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director directly owned 16,392 shares of the company’s stock, valued at $1,338,078.96. The trade was a 8.87% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently modified their holdings of the business. 180 Wealth Advisors LLC lifted its stake in shares of TransMedics Group by 14.1% in the third quarter. 180 Wealth Advisors LLC now owns 4,745 shares of the company’s stock worth $396,000 after acquiring an additional 588 shares during the period. Putney Financial Group LLC bought a new stake in TransMedics Group in the third quarter valued at approximately $161,000. Trek Financial LLC acquired a new stake in TransMedics Group during the 3rd quarter valued at approximately $11,989,000. China Universal Asset Management Co. Ltd. increased its position in TransMedics Group by 700.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 800 shares of the company’s stock valued at $67,000 after purchasing an additional 700 shares during the period. Finally, D.A. Davidson & CO. increased its position in TransMedics Group by 1.4% during the 3rd quarter. D.A. Davidson & CO. now owns 16,060 shares of the company’s stock valued at $1,340,000 after purchasing an additional 228 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.